How to Administer Levosulpiride (Lesuride) Injection
Levosulpiride injection should be administered intramuscularly (IM) at a dose of 25-50 mg twice daily, or intravenously (IV) at 25-50 mg per dose, with careful monitoring for extrapyramidal side effects.
Route of Administration
Intramuscular (IM) is the preferred route for levosulpiride injection based on the available evidence. The British Society of Gastroenterology guidelines specifically recommend levosulpiride 25 mg three times daily as a second-line treatment for functional dyspepsia, though this refers to oral dosing 1. For injectable formulations:
- IM dosing: 25-50 mg twice daily
- IV dosing: 25-50 mg per dose (when IM is not feasible)
The pharmacokinetic data demonstrates that IM administration achieves excellent bioavailability (96.8%) compared to oral administration (23.4%), with steady state reached by day 2 of multiple dosing 2.
Practical Administration Guidelines
Dosing Considerations
- Start with lower doses (25 mg) and titrate based on clinical response
- IM injections should be given in large muscle groups
- IV administration should be given slowly if used
- Monitor injection sites for signs of extravasation or local reactions
Clinical Context
For acute psychosis, the evidence shows levosulpiride can be administered at 25-50 mg/day IM for up to 5 days, though it was less effective than haloperidol for controlling agitation and aggression 3.
For functional dyspepsia as a second-line treatment, the guideline recommends careful explanation of rationale and counseling about side effects 1.
Critical Safety Monitoring
Extrapyramidal symptoms (EPS) are the primary concern with levosulpiride injection:
- Monitor for akathisia, dystonia, tremors, and parkinsonian symptoms
- EPS rates are lower with levosulpiride compared to haloperidol but still significant 3
- Recent case reports document atypical parkinsonism, periorbital tremors, and dystonia 4
- Complete remission typically occurs within 2-3 months after discontinuation 4
Additional Adverse Effects
Important Caveats
The evidence base for injectable levosulpiride is limited, with most data coming from oral formulations. The pharmacokinetic study shows that IM administration provides rapid absorption and high bioavailability, making it suitable for acute situations where oral administration is not feasible 2. However, the high incidence of adverse reactions (>50% in healthy volunteers) suggests careful patient selection and monitoring are essential 2.
Avoid prolonged use due to the risk of movement disorders. If symptoms persist beyond 5-7 days, reassess the diagnosis and consider alternative treatments.